Sanofi (NASDAQ:SNY) Downgraded by StockNews.com

StockNews.com cut shares of Sanofi (NASDAQ:SNY) from a strong-buy rating to a buy rating in a research note released on Tuesday morning.

SNY has been the subject of several other research reports. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a strong-buy rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $57.50.

Sanofi Trading Down 0.7 %

NASDAQ:SNY opened at $54.77 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market capitalization of $138.72 billion, a P/E ratio of 27.52, a P/E/G ratio of 1.56 and a beta of 0.60. The stock’s 50 day moving average price is $55.77 and its 200 day moving average price is $51.29. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 EPS. On average, research analysts forecast that Sanofi will post 4.26 EPS for the current fiscal year.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Boston Partners boosted its position in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after acquiring an additional 33,657 shares during the period. Bank of New York Mellon Corp boosted its holdings in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC grew its position in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Mondrian Investment Partners LTD increased its holdings in shares of Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. raised its position in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.